Key Points
- Director Blake Borgeson sold 30,000 Recursion Pharmaceuticals shares at an average price of $3.25, generating $97,500. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, leaving him with 6.19 million shares.
- Recursion reported a quarterly loss of $0.25 per share, slightly worse than analysts’ $0.24 estimate, while revenue of $7.67 million missed the $10.97 million consensus. The stock recently traded near $3.18, within a 12-month range of $2.77 to $7.18.
- Analyst sentiment remains mixed, with an overall “Hold” rating and an average price target of $8.10. Institutional investors own approximately 89.1% of the company, with several firms recently increasing their positions.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 30,000 shares of the company's stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $3.25, for a total value of $97,500.00. Following the sale, the director owned 6,188,287 shares of the company's stock, valued at $20,111,932.75. The trade was a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Blake Borgeson also recently made the following trade(s):
- On Tuesday, July 7th, Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.96, for a total value of $158,400.00.
- On Tuesday, June 2nd, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.68, for a total value of $110,400.00.
Recursion Pharmaceuticals Price Performance
Shares of RXRX stock opened at $3.18 on Friday. The business has a fifty day simple moving average of $3.32 and a 200 day simple moving average of $3.45. The company has a market cap of $1.69 billion, a P/E ratio of -3.06 and a beta of 1.03. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a twelve month low of $2.77 and a twelve month high of $7.18.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.01). The business had revenue of $7.67 million during the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 48.61%. During the same quarter in the prior year, the firm earned ($0.41) EPS. On average, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.9 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages recently commented on RXRX. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Morgan Stanley upped their price target on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an "equal weight" rating in a report on Thursday, May 14th. JPMorgan Chase & Co. dropped their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an "overweight" rating for the company in a research note on Thursday, April 30th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $8.10.
Get Our Latest Report on RXRX
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. Brighton Jones LLC grew its holdings in Recursion Pharmaceuticals by 49.4% during the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock worth $137,000 after acquiring an additional 6,699 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of Recursion Pharmaceuticals by 627.6% during the first quarter. Royal Bank of Canada now owns 269,013 shares of the company's stock worth $1,423,000 after purchasing an additional 232,038 shares during the period. AQR Capital Management LLC acquired a new position in shares of Recursion Pharmaceuticals during the first quarter worth $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Recursion Pharmaceuticals by 7.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company's stock worth $953,000 after purchasing an additional 12,372 shares during the last quarter. Finally, Focus Partners Wealth bought a new stake in shares of Recursion Pharmaceuticals in the first quarter worth $77,000. Institutional investors own 89.06% of the company's stock.
Trending Headlines about Recursion Pharmaceuticals
Here are the key news stories impacting Recursion Pharmaceuticals this week:
- Positive Sentiment: Genentech advanced the collaboration’s first neuroscience target into a joint early-discovery program, providing early validation of Recursion’s platform. The company also reported that REC-7735 received IND clearance, with its Phase 1/2 ZINNIA trial expected to begin in the second half of 2026. Recursion Reports Second Quarter Financial Results
- Positive Sentiment: Management highlighted upcoming clinical catalysts, including additional REC-4881 Phase 2 data in November 2026 and further Phase 1 updates for REC-1245. Recursion also emphasized that its AI-native platform produced REC-7735 rapidly, supporting the long-term technology investment case. Recursion outlines 2026 cash OpEx guidance
- Positive Sentiment: The quarterly loss narrowed year over year to $0.25 per share from $0.41, while Recursion reduced its 2026 cash operating-expense guidance to approximately $375 million, potentially improving cash-burn visibility. RXRX mixed Q2 results and Genentech milestone
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
